New entity will be majority owned by Emergent BioSolutions.

Emergent BioSolutions and Ninebio have formed a joint venture in Malaysia that will focus on creating biologics infrastructure and supplying biodefense countermeasures. The joint venture will be majority owned by Emergent BioSolutions.

The companies expect to also provide these products and services to certain member countries of the Organisation of the Islamic Conference (OIC) and other nations within Asia. 

The Malaysian Government owns and funds Ninebio. Through Ninebio, the Government selected Emergent BioSolutions as one of its principal partners to assist as a contract service provider in building vaccine development and manufacturing infrastructure. Besides Emergent BioSolution’s anthrax vaccine, BioThrax®, other medical and complementary products and services will be supplied to the Government of Malaysia.

“It is our belief that this joint venture will not only expand the use of our anthrax vaccine in this market but will also serve as a platform for joint product development and manufacturing activities,” remarks Fuad El–Hibri, chairman and CEO of Emergent BioSolutions.

Previous articleGSK and TB Alliance Extend Discovery Partnership by Three Years
Next articleCobra to Support Manufacturing of GenVec’s Late-Stage Cancer Therapy